PDF(Pubmed)
Abstract：
Ischemic stroke (IS) exhibits significant heterogeneity in terms of etiology and pathophysiology. Several recent studies highlight the significance of inflammation in the onset and progression of IS. White blood cell subtypes, such as neutrophils and monocytes, participate in the inflammatory response in various ways. On the other hand, high-density lipoproteins (HDL) exhibit substantial anti-inflammatory and antioxidant actions. Consequently, novel inflammatory blood biomarkers have emerged, such as neutrophil to HDL ratio (NHR) and monocyte to HDL ratio (MHR). Literature research of two databases (MEDLINE and Scopus) was conducted to identify all relevant studies published between 1 January 2012 and 30 November 2022 dealing with NHR and MHR as biomarkers for IS prognosis. Only full-text articles published in the English language were included. Thirteen articles have been traced and are included in the present review. Our findings highlight the utility of NHR and MHR as novel stroke prognostic biomarkers, the widespread application, and the calculation of which, along with their inexpensive cost, make their clinical application extremely promising.
摘要：
缺血性卒中（IS）在病因和病理生理学方面表现出明显的异质性。最近的几项研究强调了炎症在IS发作和进展中的重要性。白细胞亚型,如中性粒细胞和单核细胞，以各种方式参与炎症反应。另一方面,高密度脂蛋白(HDL)具有显著的抗炎和抗氧化作用。因此,新的炎症血液生物标志物已经出现，例如中性粒细胞与HDL比率(NHR)和单核细胞与HDL比率(MHR)。对两个数据库（MEDLINE和Scopus）进行文献研究，以确定2012年1月1日至2022年11月30日发表的所有相关研究，涉及NHR和MHR作为IS预后的生物标志物。仅包括以英语发表的全文文章。已经追踪了13篇文章，并包括在本评论中。我们的发现强调了NHR和MHR作为新型卒中预后生物标志物的实用性，广泛应用，以及其中的计算，加上他们便宜的成本，使其临床应用前景极为广阔。
